On September 24, 2026, Men's Health published a feature arguing that the male "sexual prime" has been misattributed to testosterone for decades — and the numbers it cites are a direct problem for the TRT telehealth industry. The piece reports that prescriptions for testosterone have risen 154% since 2020, concentrated among men in their late thirties and forties, a surge it attributes to the combination of manosphere content and the proliferation of TRT telehealth clinics in the United States.

Why It Matters

The TRT telehealth boom is built on a causal story — declining testosterone causes declining sexual function, therefore restore the hormone — and the largest representative dataset on desire does not support it as the primary mechanism. That is an uncomfortable position for a category that has scaled on paid social advertising to exactly the late-thirties and forties demographic driving the 154% prescription increase. If relationship satisfaction and sleep outperform hormone levels as predictors, the honest product is a sleep intervention or couples therapy, not a subscription injection. For the rest of the male sexual health segment, the implication is more favorable and points the same direction as recent research Afterglow has covered. A Psychology & Sexuality study reported September 23 found relationship balance and satisfaction — not testosterone — moving male desire outcomes. LELO has begun bundling guided Kegel training into the F2S Double Sonic. Mojo and Lover sell behavioral and psychological interventions for performance anxiety. The evidence base is converging on the unglamorous stuff: sleep, relationship quality, stress, and the mental-versus-physical distinction that determines whether a PDE5 inhibitor is the right tool at all. There is also a regulatory overhang worth watching. The FDA held a public workshop on testosterone in menopausal women on September 17 with a comment period closing October 19, and the Pentagon has moved on testosterone screening for troops. Prescribing surges of this magnitude, in a category with documented dependence dynamics and thin monitoring, are the kind of thing FTC enforcement and state medical boards eventually notice.

The counter-evidence comes from Toivo Aavik, an associate professor of psychology at the University of Tartu who studies sexual behavior and men's health. Aavik's team published "Associations of Sexual Desire with Demographic and Relationship Variables" in Scientific Reports on January 5, 2026 — a study of 67,334 Estonian Biobank participants, one of the largest representative samples ever assembled on the question. Their multivariate models explained 28.3% of the variance in sexual desire, with gender and age the strongest predictors. Aavik's framing of the popular error is precise: "Testosterone is highest in young adulthood; therefore, sexual desire must also be highest then. But low sexual desire is not evidence of low testosterone."

Aavik told Men's Health that men's sexual desire actually peaks around 40 and stays relatively stable until 60, with midlife libido depending more on relationship satisfaction, past masturbation frequency, and physical health factors like stress and sleep than on testosterone alone. He is careful about what the design supports: his team did not track individual men's testosterone longitudinally, and instead surveyed self-reported desire across ages 20 to 84 and cross-referenced it against what is already established about age-related testosterone decline. The defensible claim is therefore stability — the libido a man has in his twenties and thirties holds roughly steady until his sixties — rather than a literal increase at 40. Aavik also notes that low desire is not automatically pathological: "Some people simply have less sexual desire than others, and this is not necessarily a medical problem."

The clinical critique in the piece is sharper than the usual wellness-media hedging. It notes that heightened testosterone can convert to estrogen and itself cause erectile dysfunction; that TRT signals the brain to stop producing testosterone naturally, creating treatment dependence; and that clinics often prescribe to men with borderline-normal levels without adequate monitoring. San Francisco urologist Judson Brandeis points to sleep as the dominant modifiable factor in men under 60, since luteinizing hormone production happens during sleep, and reports seeing hormonal imbalance concentrated in night-shift workers and men in highly physical trades rather than simply older men. His diagnostic triage for men presenting with performance concerns: fix sleep, monitor spontaneous erection frequency to separate psychological from biological ED, and get comprehensive bloodwork through a physician rather than self-managed DTC panels.

Sources

Update — 2026-09-25

{Initial entry — story first created.}